Modality
Fusion Protein
MOA
MDM2i
Target
CGRP
Pathway
Complement
RCC
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
Apr 2017
→ Jul 2029
Phase 1Current
NCT08564391
882 pts·RCC
2017-12→2029-07·Terminated
NCT05966276
1,294 pts·RCC
2017-04→2028-12·Not yet recruiting
2,176 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-12-262.7y awayPh2 Data· RCC
2029-07-253.3y awayPh2 Data· RCC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Not yet…
P1/2
Termina…
Catalysts
Ph2 Data
2028-12-26 · 2.7y away
RCC
Ph2 Data
2029-07-25 · 3.3y away
RCC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08564391 | Phase 1/2 | RCC | Terminated | 882 | ACR20 |
| NCT05966276 | Phase 1/2 | RCC | Not yet recr... | 1294 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 |